FDA-approved

Hormones & metabolism

Tesamorelin

Evidence

FDA approved

Class

Growth hormone-releasing hormone analog

/

Tesamorelin

KEY TAKEAWAY

Tesamorelin is a growth hormone-releasing hormone analog approved to reduce excess abdominal fat in adults with HIV-associated lipodystrophy.

Written by the Veylo editorial team · Updated

November 2026

At a glance

At a glance

What it is

A synthetic analog of growth hormone-releasing hormone

Approved for

Excess abdominal fat in HIV-associated lipodystrophy

Key fact

Reduced visceral abdominal fat in a randomized trial

Route

Daily injection

Evidence strength

FDA approved

What it is

What it is

Tesamorelin, sold as Egrifta, is a modified version of the 44-amino-acid hormone that triggers growth hormone release.

How it works

How it works

It stimulates the pituitary gland to release growth hormone, which raises IGF-1 and helps the body break down visceral fat.

Regulatory status

Regulatory status

The FDA approved tesamorelin in 2010 for reducing abdominal fat in adults with HIV-associated lipodystrophy. It is not approved for general weight loss.

What it is used for

What it is used for

Visceral fat reduction in adults with HIV on antiretroviral therapy. Other uses are investigational.

Side effects and risks

Side effects and risks

Joint pain, swelling, muscle aches and injection-site reactions occur. It can raise blood sugar and should not be used in active cancer.

Citations

Citations

Falutz J et al. Metabolic effects of a growth hormone-releasing factor in patients with HIV. N Engl J Med. 2007;357:2359-2370.

Veylo content is educational and not medical advice. Peptides that are not FDA-approved are not approved for the uses described.

Veylo

Clinician-guided peptide care, paired with baseline blood testing and ongoing support.

Peptides referenced on this site are compounded medications and are investigational; they have not been approved by the FDA for the uses described. Nothing here is medical advice. Prescriptions are issued only after a licensed clinician reviews your history.

© 2026 Veylo. All rights reserved.

Veylo

Veylo

Veylo